Study In European Heart Journal Favors TAXUS(R) Stent Over Cypher(R) Stent And Bare-Metal Stents In Diabetic Patients

... Boston Scientific Corporation (NYSE: BSX) today welcomed the results of an independent study demonstrating that Boston Scientific's TAXUS(R) paclitaxel-eluting stent (PES) exhibited a lower re-intervention rate and equal or lower instances of death or heart attack than the Cypher(R) sirolimus-eluting stent (SES) and bare- metal stents (BMS). [click link for full article] ...